A look at the potential of menin inhibitors for patients with acute myeloid leukemias, specifically Syndax Pharmaceuticals' revumenib and how it compares to Kura's ziftomenib.

Executed on:Aug 19, 2024 10:00 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Fred Hutchinson Cancer CenterProfessor in the clinical research division, Endowed Chair for Cancer Research at Fred Hutchinson Cancer Center  & Professor of Medicine at the University of Washington.
Currently manages over 50 patients with AML.
Research involves developing improved antibody-based therapies in the laboratory that effectively kill AML cells, including treatments that eradicate AML stem cells.

Interview Goal

On this call we will be discussing the recent Phase 1/2 data updates from Syndax's trials of revumenib in AML as well as discussing how it compares to Kura's menin inhibitor, ziftomenib.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.